MNPR — Monopar Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $274.94m
- $214.73m
- 38
- 24
- 63
- 36
Annual balance sheet for Monopar Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 16.7 | 20.3 | 13.1 | 7.27 | 60.2 |
| Total Other Current Assets | |||||
| Total Current Assets | 16.8 | 20.5 | 13.2 | 7.33 | 60.3 |
| Net Property, Plant And Equipment | — | — | 0.061 | 0.013 | 0 |
| Other Long Term Assets | |||||
| Total Assets | 16.9 | 20.5 | 13.2 | 7.35 | 60.3 |
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 1.18 | 1.58 | 3.13 | 1.76 | 5.25 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1.18 | 1.58 | 3.14 | 1.76 | 5.25 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 15.7 | 18.9 | 10.1 | 5.59 | 55 |
| Total Liabilities & Shareholders' Equity | 16.9 | 20.5 | 13.2 | 7.35 | 60.3 |
| Total Common Shares Outstanding |